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ABSTRACT
Aptamers binding proteins or small molecules
have been shown to be versatile and powerful
building blocks for the construction of artificial
genetic switches. In this study, we present a novel
aptamer-based construct regulating the Tet Off
system in a tetracycline-independent manner thus
achieving control of transgene expression. For this
purpose, a TetR protein-inhibiting aptamer was
engineered for use in mammalian cells, enabling
the RNA-responsive control of the tetracycline-
dependent transactivator (tTA). By rationally
attaching the theophylline aptamer as a sensor,
the inhibitory TetR aptamer and thus tTA activity
became dependent on the ligand of the sensor
aptamer. Addition of the small molecule theophyl-
line resulted in enhanced binding to the correspond-
ing protein in vitro and in inhibition of reporter gene
expression in mammalian cell lines. By using
aptamers as adaptors in order to control protein
activity by a predetermined small molecule, we
present a simple and straightforward approach for
future applications in the field of Chemical Biology.
Moreover, aptamer-based control of the widely used
Tet system introduces a new layer of regulation
thereby facilitating the construction of more
complex gene networks.
INTRODUCTION
Aptamers are short nucleic acids binding ligands with high
afﬁnity (1). They can be artiﬁcially designed by a method
called Sytematic Evolution of Ligands by Exponential
Enrichment to recognize a wide variety of ligands
ranging from small molecules to intracellular proteins
and cell-surface epitopes (1). Upon ligand binding, a con-
formational change of the aptamers’ secondary structure
can be induced (2). This has been broadly used to con-
struct molecular sensors detecting the corresponding
ligand in vitro (3).
Moreover, aptamers have been shown to be capable of
regulating gene expression in bacteria and eukaryotes. In
2002, more than 10 years after the ﬁrst artiﬁcial aptamers
have been reported (4), natural aptamer domains were
discovered as part of so-called riboswitches. Located in
the untranslated regions (UTRs) of messenger RNAs
(mRNAs), riboswitches affect transcription or translation
by a ligand-induced change of mRNA secondary struc-
tures (5,6). Moreover, artiﬁcial gene regulation systems
have been designed by sophisticated incorporation of
aptamers in natural systems. In bacteria, the conform-
ational change of an aptamer is used to mask the
ribosome-binding site on the mRNA thus affecting trans-
lation initiation (7,8). In eukaryotes, ligand binding to the
aptamer can result in a stabilized secondary structure,
which can be used to block ribosomal mRNA scanning
(9,10), dicer processing (11) or splicing (12,13). Also,
aptamers fused to ribozymes have been validated as ver-
satile control devices in bacteria (14–17) as well as in eu-
karyotes (18–21). It has to be noted that even though a
vast variety of aptamers is existing, many of these syn-
thetic riboswitches contain the well-characterized theo-
phylline aptamer, which has ﬁrst been described in 1994
and binds its ligand with a Kd=320nM (22). Interes-
tingly, this aptamer has a 10000-fold lower afﬁnity to
caffeine, the methylated derivative of theophylline (22).
Additionally, gene expression control was obtained by
applying aptamers speciﬁc for transcription factors. Often
based on a yeast-three-hybrid system, there the aptamer is
part of a larger RNA construct and has the mission to
recruit an essential transcription factor to the cognate
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demonstrated, that a tetramethylrhosamine-speciﬁc
aptamer could regulate such transcription factor recruit-
ment and trigger gene expression in yeast accordingly.
However, in vivo selection was required to identify a
suitable connection sequence linking the RNA domains
(26), the speciﬁc aptamer–protein interaction site
remained elusive (23,26).
Besides their role in artiﬁcial gene regulation, protein-
binding aptamers have been shown to modify protein
functionality in vitro and in vivo (27–30). Prominent
examples include the inhibition of the fruit ﬂy splicing
factor B52 (28), yeast RNA polymerase II (29) and
reverse transcriptase of HIV-1 (27,30). Such aptamers
could also be used to identify small-molecule inhibitors
of the target protein by a method known as aptamer dis-
placement (31). Also, aptamers speciﬁc for intracellular
target proteins (intramers) have been used for protein-
function analysis (32).
In this study, we have successfully designed a small
molecule-responsive mammalian intramer, which could
modulate protein function in a trigger-inducible manner.
In such a conﬁguration, the intramer serves as a universal
adaptor attenuating protein activity in response to a
speciﬁc dose of a desired small molecule.
MATERIAL AND METHODS
Plasmid design
The functional and the inactive control variants
of the TetR aptamer (33) were inserted into ‘pRzTheo-
miREGFP M5’ (kindly provided by Prof.
Dr Yokobayashi, UC Davis) (34) by polymerase chain
reaction (PCR)-mediated cloning using sequence-speciﬁc
primers containing the TetR aptamer sequences at their
50-end (underlined). In brief, immediately after the PCR
(Phusion, Finnzyme), the template plasmid was digested
using the restriction enzyme DpnI. The aptamer-
containing PCR fragments were ligated (T4 DNA
Ligase, Fermentas) and transformed into Escherichia coli
XL10 gold (Stratagene). Single colonies were picked and
grown in LB-medium supplemented with 100mgml
 1
ampicillin (Roth). To conﬁrm successful assembly, the
cloned plasmids were isolated (Miniprep Kit, Zymo
Research) and sequenced. For the primers used for
cloning, see Table 1. The constructed aptamer-harboring
plasmids pDAX were denominated as follows: pDA1
(active TetR aptamer), pDA3 (inactive TetR aptamer),
pDA4 (theophylline-responsive TetR aptamer) and
pDA15 and pDA16 (different connector lengths of
theophylline-responsive TetR aptamer).
Cell culture
Human embryonic kidney cells HEK293-T (American
Type Culture Collection, ATCC No. CRL-11268)
were cultured in Dulbecco’s Modiﬁed Eagle’s Medium
supplemented with 10% (v/v) Fetal Calf Serum (FCS)
(PAN Biotech; lot no. P231902) and 1% (v/v) penicillin/
streptomycin solution (PAN Biotech). Chinese hamster
ovary cells (CHO-K1, ATCC No. CCL-61) were cultivated
in ChoMaster HTS (Cell Culture Technologies) supple-
mented with 5% (v/v) FCS and 1% penicillin/streptomycin
solution. All cell lines were incubated at 37 Ci na
humidiﬁed atmosphere containing 5% CO2.
Transfection
One day prior to transfection 50000 cells per well were
seeded into a 24-well plate containing 0.5ml medium.
HEK293-T were cotransfected with 800ng total DNA
[pSAM200 (35):pMF111 (36):pDAX=1:1:14] using a
standard CaPO4 transfection protocol. (37) In brief,
plasmids were mixed in 12.5ml sterile water, an equal
volume of sterile 0.5 M CaCl2 was added and incubated
for 15min. Thereafter, 25ml of sterile 2 HBS (100mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.05;
280mM NaCl, 1.5mM Na2HPO4) was added while vor-
texing and subsequently added dropwise to the cells. After
an incubation time of 4h, fresh medium supplemented
with appropriate concentrations of theophylline was
added. CHO-K1 cells were transfected with Fugene 6
(Roche Diagnostics AG) according to the manufacturer’s
protocol. Reporter gene expression was evaluated 48h
after transfection.
Colorimetric SEAP assay
Cell culture supernatant was ﬁrst heat inactivated for
30min at 65 C and centrifuged at 2000rpm for 5min to
remove cell debris. A total of 100mlo f2  SEAP assay
buffer (20mM homoarginine, 1mM MgCl2, 21%
diethanolamine pH 9.8) was mixed with 80mlo f
heat-inactivated cell culture supernatant. 20ml substrate
solution [120 mM p-nitrophenylphosphate (pNPP, Sigma
Chemie)] was added and absorbance was measured at
405nm (p-nitrophenol; pNP) at 37 C for 30min from
which SEAP activity can be calculated as described else-
where (38).
Reverse transcription–polymerase chain reaction
HEK293-T cells were cotransfected as described above
with plasmids as indicated in Figure 2C. Total RNA
was isolated from cells after 48h using TRIzol Reagent
(Invitrogen) following the manufacturer’s protocol.
Subsequently, RNA was treated with 2 U DNase I
(Fermentas) to remove residual DNA contaminations.
One microgram DNaseI-treated RNA and SuperScript
II RT (Invitrogen) were used to generate cDNAs using
speciﬁc primers ODA64_GAPDH_rv (50-GGCATGGAC
TGTGGTCATGAG) and ODA66_invitro_rv3 (50-GGG
AGATACGCGTATCAAG) for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and TetR
aptamers, respectively. Twenty ﬁve cycles of PCR were
carried out using following primers: ODA63_GAPDH_
fw (50-ACAGCTACTCCTCGCCTGTG) and ODA64_
GAPDH_rv giving an amplicon length of 87 bp for
GAPDH, ODA38-in_vitro_Fw and ODA66_invitro_rv
giving amplicon lengths of 72 bp for pDA1/pDA3 and
87 bp for pDA4. PCR products were separated on 3%
agarose gels supplemented with ethidium bromide and
visualized under UV light.
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The open reading frame of TetR was cloned with NdeI/
HindIII into pET30a in frame to a 50-hexahistidine
sequence and the plasmid was transformed into E. coli
BL21/Gold (DE3). One millimolar Isopropyl b-D-1-
thiogalactopyranoside was added, when the bacterial
culture reached OD600=0.8. Cells were harvested by cen-
trifugation after 3–4h expression at 30 C and resuspended
in lysis buffer (25mM NaH2PO4, 100mM NaCl, 10mM
Imidazol pH 8). Cell were lysed by French Press and sub-
sequently loaded onto a 1ml Ni
2+-NTA column (GE
Healthcare) equilibrated with lysis buffer. TetR was
eluted by gradually increasing the imidazole concentration
to 500mM (see Ni-NTA Spin Kit Handbook, www.
qiagen.com). The peak fractions were analyzed by SDS–
PAGE, pooled and protein was dialyzed in 25mM
NaH2PO4, 100mM NaCl, 25% glycerol pH 8 overnight
and subsequently stored at  20 C until use.
RNA preparation
Synthetic DNA template of theo-TetR intramer was
PCR-ampliﬁed using the following primers: ODA37_
in_vitro_rv: TAATACGACTCACTATAGGGAGATAC
GCGTATCAAG, ODA38-in_vitro_Fw: CTCCTTTCGC
GTATCAAGC and the plasmid pDA4 as a template. The
PCR product was in vitro transcribed using T7 RNA poly-
merase (Fermentas) in transcription buffer (40mM Tris–
HCl pH 7.9, 6mM MgCl2, 10mM DTT, 10mM NaCl,
2mM spermidine, 2mM ATP, 2mM CTP, 2mM GTP
and 2mM UTP). After 4h of incubation at 37 C the
reaction was stopped by addition of one volume of stop
buffer [80% (v/v) formamide, 50mM EDTA pH 8.0,
0.025% (w/v) bromophenolblue and 0.025% (w/v)
xylene cyanole]. Subsequently the product was puriﬁed
Table 1. Primer sequences used for the construction of the aptamers
Plasmid name Primer names and sequences Template
pDA1—TetR aptamer ODA10 pRzTheo-miREGFP M5
50-CACAGACCAGAGAAAAGCTTGATACGCGAAAGGAG
TTTTTT GGAAAAGCTTGGCACTGGC-30
ODA11
50-Pho-ATGACCCATAACATGCTGCTTGATACGCGTATCTCCCTC
GATCCCGCGTCCTTTCCACAAG-30
pDA3—inactive TetR
aptamer
ODA11 pRzTheo-miREGFP M5
ODA13
50-CACAGACCATAGAAAAGCTTGATACGCGAAAGGAG TTTTTT
GGAAAAGCTTGGCACTGGC-30
pDA4—
theophylline-responsive
TetR aptamer—2 GC
ODA14 pDA1
50-GGATACCAGCCGAAAGGCCCTTGGCAGCC
AGAGAAAAGCTTGATACGC-30
ODA15
50-Pho-CATAACATGCTGCTTGATACG-30
pDA15—
theophylline-responsive
TetR aptamer—1 GC
ODA30 pDA1
50-GATACCAGCCGAAAGGCCCTTGGCAGC
AGAGAAAAGCTTGATACGC-30
ODA15
pDA16—
theophylline-responsive
TetR aptamer—3 GC
ODA31 pDA1
50-GGGATACCAGCCGAAAGGCCCTTGGCAGCCC
AGAGAAAAGCTTGATACGC-30
ODA15
Figure 1. (A) Proposed mechanism of the theophylline-responsive TetR
aptamer. In presence of theophylline the TetR aptamer structure is
restored. This allows for speciﬁc binding to tTA thus inhibiting tran-
scription initiation. PhCMVmin* 1 stands for tetracycline responsive
promoter, SEAP for secreted alkaline phosphatase and pA for
poly(A)-tail. (B) Plasmid constructs used in this work. pDAX encodes
either pDA1 (active TetR aptamer), pDA3 (inactive TetR aptamer) or
pDA4 (theophylline-responsive TetR aptamer). pSAM200 encodes tTA,
pMF111 contains a PhCMV* 1-driven SEAP expression unit.
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excised and isolated from the gel.
Competition assay
For competition assays, two complementary oligonucleo-
tides ODA68 (Cy5-TTGACACTCTATCATTGATAGA
GTTAT) and ODA69 (ATAACTCTATCAATGATAG
AGTGTCAA) containing the tet operator sequence were
hybridized in 1x annealing buffer [20 mM Tris–HCl
(pH 7.8), 5mM MgCl2 and 50mM NaCl] by heating to
95 C and slowly cooling down to RT for 30min. One
ninety nanomolar Cy5-labeled DNA was then incubated
in electrophoretic mobility shift assays (EMSA) buffer [20
mM Tris–HCl (pH 7.8), 5mM MgCl2, 50mM NaCl,
0.5mg/ml polydI:dC, 20% glycerol] with indicated
amounts of protein, RNA aptamers, theophylline and
anhydrotetracycline (atc). After a 15min incubation
period at room temperature, samples were electrophoresed
at 4 C on a 10% polyacrylamide gel containing 0.5% Tris-
borate-EDTA buffer.
Determination of the equilibrium dissociation constants
Kd and Kc
Dissociation constant Kd of the His-tag TetR to its DNA
operator was determined by quantifying the gel shift assay
with ImageJ. Data obtained was ﬁtted to
f ¼ m Cn ðKn
d+CnÞ
 1 ð1Þ
with f=fraction bound, C=concentration of the TetR
protein, n=Hill coefﬁcient and m=maximal levels of
fraction bound.
Dissociation constants of the competitors Kc of the
aptamer variants were determined by quantifying the com-
petition assays with ImageJ. From the data obtained,
the concentration of aptamer that disrupts 50% of the
protein–DNA complex (IC50) was calculated with the
following equation (39)
f ¼ b+ððm   bÞ
 ð1+ðIC
 
50Cð nÞÞÞ
 1Þð 2Þ
with f=fraction bound, C=concentration of the
aptamer variant, n=Hill coefﬁcient and m and b
maximal and minimal levels of fraction bound.
The IC50 value was then used to calculate Kc using the
Lin and Riggs equation (39,40)
Kc ¼ð 2
 K 
dIC50Þ
 ð2
 P   R   2 KdÞ
 1 ð3Þ
with Kd=dissociation constant of the His-tag TetR to its
DNA operator, P=His-tag TetR concentration and
R=labeled DNA operator concentration.
RESULTS AND DISCUSSION
The modular nature of aptamers enables the rational
design of allosteric multi-domain variants such as those
containing interconnected sensor and effector domains
(41). Upon binding of the trigger to the sensor domain
Figure 2. The TetR aptamer in mammalian cells. (A) Nucleotide sequence and secondary structure of the TetR aptamer variant 12-1R adapted from
Hunsicker and colleagues (33). Boxed nucleotide indicates an inactivating point mutation (33). (B) Transcription of the TetR aptamer in HEK293-T
cells signiﬁcantly represses reporter gene expression compared to the genetically inactivated control variant. (C) Analysis of RNA expression of
different TetR aptamer constructs in HEK293-T cells by semi-quantitative RT–PCR showed comparable expression levels of all constructs.
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domain for the desired action (41). As a proof-of-principle
design for trigger-inducible intramers, we chose the well-
characterized theophylline aptamer (22) as the sensor
domain and the TetR-tetO-inhibiting intramer as effector
domain (33,42). In mammalian cells, TetR fused to the
VP16 transactivation domain (tTA, tetracycline-dependent
transactivator) and the heptameric tetO [(tetO)7] fused to a
minimal promoter (PhCMV* 1, tetracycline-responsive
promoter) are known as the TET system (43) and represent
frequently used parts for tetracycline-dependent transgene
control and synthetic gene networks (44). Therefore, the
design of a ligand-responsive intramer would add an
additional layer of regulation and expand the use of the
TET system by introducing a new inducer molecule, see
Figure 1A.
Transfer of TetR aptamer into mammalian cells
Evolved in a combined in vitro/in vivo approach, the TetR
aptamer (see Figure 2A for sequence and secondary struc-
ture) was shown to induce transcription in E. coli by
competing with TetR for binding with the tetO operator
sequence by masking the tetO-binding helix-turn-helix
Figure 3. In vivo characterization of the theo-TetR intramer. (A) Nucleotide sequence and secondary structure of the theo-TetR intramer. The 5’-
and 3’-stem region is identical to Figure 2A and, thus, denoted as black points. (B) Theo-TetR intramer-responsive reporter gene expression levels in
the absence (blue column) and in the presence of 2mM theophylline (red column). The rationally designed connection sequence has a strong inﬂuence
on the performance of the device. (C) Speciﬁcity and cytotoxicity of the system. In contrast to theophylline, caffeine does not speciﬁcally repress
SEAP expression. However, due to their cytotoxicity, both compounds reduce overall gene expression by 25%.
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shown to inﬂuence aptamer activity, we chose the
best-characterized TetR aptamer variant 12-1R (33) for
initial experiments. In a ﬁrst step, we had to engineer
this system for use in mammalian cells. Therefore, the
TetR intramer was placed under control of the RNA poly-
merase III-dependent U6 promoter (pDAX). Since U6
promoter transcripts used in this study are devoid of any
export signal corresponding aptamers remain in the
nucleus. tTA was expressed constitutively from a second
plasmid (pSAM200) while the reporter gene SEAP was
driven by PhCMV* 1 (pMF111) of a third plasmid
(Figure 1B). After binding of tTA to tetO7, gene expres-
sion should be induced. Indeed, tTA in combination with
an inactivated control TetR aptamer (33) resulted in efﬁ-
cient gene expression. However, with aptamer functional-
ity restored, SEAP expression was shut down (Figure 2B).
Semi-quantitative reverse transcription–polymerase chain
reaction (RT–PCR)-based control experiments showed
that these aptamer variants were expressed at similar
levels (Figure 2C), conﬁrming that differences in SEAP
production proﬁles correlated with changes in aptamer
afﬁnity. This basic experiment demonstrated the
cross-kingdom interoperability of aptamers. Noteworthy,
unlike in bacteria where the TetR aptamer induces gene
expression when competing with TetR binding (33), it
represses transgene expression in mammalian cells by in-
hibiting the tTA-tetO7 interaction.
Theophylline-responsive TetR aptamer in mammalian cells
In order to obtain a controllable intramer (‘theo-TetR
intramer’), we replaced its stem–loop region of the TetR
aptamer, which is not involved in ligand binding (33), by
the theophylline aptamer (22) (Figures 1A and 3A). A
central element of this novel RNA construct was the con-
nection sequence linking the two domains. Only the
presence of theophylline should induce the deﬁned TetR
aptamer structure that is capable of binding the corres-
ponding protein. Using the secondary structure prediction
algorithm mfold (45), we designed this connector sequence
to be a short unstable stem region that does not interfere
with the overall aptamer structure, see Figure 3A.
Figure 4. (A) Theophylline dose-dependent inhibition of SEAP expression of the theo-TetR intramer (red) relative to the inactivated TetR intramer
variant (blue) in HEK293-T cells. (B) Theophylline and doxycycline cross-titration of the theo-TetR intramer in HEK293-T cells. Intersection points
of the grid represent SEAP expression levels measured in duplicates.
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expected in vivo. In the absence of theophylline, the
theo-TetR intramer does not inhibit tTA which therefore
mediates maximum transgene expression, almost compar-
abletolevelsreachedwhenusingthegeneticallyinactivated
control intramer. However, after the addition of theophyl-
line, SEAP expression is dose-dependently reduced and
reaches a repression level typically achieved by using the
native TetR intramer (Figures 3B and 4A). The speciﬁcity
was demonstrated by the addition of the theophylline
homologue caffeine, which did not modulate aptamer
function (Figure 3C). The importance of the connection
sequence was demonstrated by further mutational
analysis: destabilization of the active fold by removing
one base pair of the connection sequence resulted in
increased SEAP levels. The opposite effect was observed
by introducing an additional base pair, thus following a
predictable rational in which the connector stability
directly correlates with the formation of the active TetR
aptamer structure, see Figure 3B.
Also, comparable switching rates were achieved follow-
ing co-transfection of the constructs into different host cell
lines (HEK293-T and CHO-K1 cells; Figure 3B).
Noteworthy, we observed theophylline-dependent cyto-
toxicity in both cell types resulting in an unspeciﬁc 25%
reduction of reporter gene expression (Figure 3C). This is
in accordance with previous reports using theophylline in
mammalian cells (11,18,21), thus highlighting the need for
novel aptamers responsive to non-toxic compounds.
A cross-titration of the theo-TetR intramer with
theophylline and doxycycline, which represses gene ex-
pression in the tTA system, revealed both effectors to be
Figure 5. In vitro competition assays of RNA aptamers withCy5-labeled dsDNA tetO for TetR binding. (A) Quantiﬁcation of
concentration-dependent binding of puriﬁed TetR protein to tetO resulted in an apparent Kd=60nM. TetR was released from DNA upon
addition of tetracycline. (B) While the inactive TetR aptamer has no inﬂuence, the active variant competes with tetO for TetR binding independent
of theophylline (Kc,no theo=58nMandKc, 2 mM theo=76nM). Binding of the theophylline-responsive variant to TetR, however, is strongly improved
in the presence of 2mM theophylline (Kc,no theo=276nM and Kc, 2 mM theo=106nM). (C) Theophylline-dependent competition of theo-TetR
intramer with tetO for TetR binding. If not stated separately, TetR concentration was kept constant at 340nM, tetO at 190nM and theo-TetR
intramer at 275nM.
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should allow the application of the newly constructed
intramer in numerous synthetic gene networks based on
the tTA system (44).
In vitro characterization of the theo-TetR intramer
We further characterized the theo-TetR intramer by per-
forming in vitro-binding studies. Since the original TetR
aptamer binds speciﬁcally to the DNA-binding domain of
TetR (33), we also used the latter protein for the in vitro
studies. Using EMSA, His-tagged TetR protein
that was puriﬁed from E. coli was shown to bind to a
Cy5-labeled dsDNA harboring the tetO sequence in a
tetracycline-responsive manner. Compared to the
wt-TetR (Kd=5.6nM) (46), the His-tagged variant ex-
hibited a slightly lower binding afﬁnity (Kd=60nM;
Figure 5A). As shown before (33), TetR binding to the
tetO dsDNA can be competed with increasing concentra-
tions of wt-TetR aptamer. However, addition of the
inactive TetR aptamer variant had no inﬂuence on
TetR-tetO binding. In vitro competition assays supported
the in vivo observations, that the presence of theophylline
had no inﬂuence on the TetR-binding characteristics of
both, active and inactive aptamer variants (Figure
5B).Although the theo-TetR aptamer showed lower
target afﬁnity (Kc=276nM) compared to the wt-TetR
aptamer (Kc=58nM), its TetR-binding capacity could
be adjusted by theophylline to Kc,theo=106nM. By
adding increasing concentrations of the ligand the
aptamer could compete with tetO for Tet repressor
protein binding (Figure 5B and C).
In summary, we designed and constructed a ligand-
responsive intramer for adjustable transgene expression
in mammalian cells. By rationally replacing a stabilizing
stem-loop structure of the TetR intramer with the theo-
phylline aptamer, we achieved an RNA construct that
allows regulation of TetR/tTA protein function by an
external ligand. The resulting artiﬁcial RNA switch
shows a 5-fold inhibition of gene expression, which is in
the same range of other types of RNA switches con-
structed for mammalian cells (11,21). Since the tTA
system is an essential part of many synthetic genetic
networks (44,47,48), the presented theo-TetR intramer
offers a simple but promising way to introduce a new
layer of regulation. The possibility to control the same
gene output by two different molecule inputs will facilitate
the construction of more complex synthetic gene networks
in future. This is from greatest interest for cellular Boolean
calculations but could also be used as a safeguard in
microencapsulated cell implants where one input allows
a concentration-dependent ﬁne-tuning of therapeutic
protein expression while the second input resets the
system.
Also, the basic principle of building a small molecule-
responsive regulator of distinct protein functions via
rational design could be valuable for the ﬁelds of
Synthetic and Chemical Biology. In future experiments,
we will try to generalize this principle by using intramers
targeting other proteins not exclusively involved in gene
regulation.
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